Therapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elements by unknown
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Abstract
Background: Endoretroviruses account for circa 8 % of all transposable elements found in the genome of humans
and other animals. They represent a genetic footprint of ancestral germ-cell infections of exoviruses that is
transmittable to the progeny by Mendelian segregation. Traces of human endogenous retroviruses are
physiologically expressed in ovarial, testicular and placental tissues as well as in stem cells. In addition, a number of
these fossil viral elements have also been related to carcinogenesis. However, a relation between endoretroviruses
expression and chemoresistance has not been reported yet.
Methods: Twenty colorectal carcinoma patient samples were scrutinized for HERV-WE1 and HERV-FRD1 endoretroviruses
using immunohistochemical approaches. In order to search for differential expression of these elements in chemotherapy
refractory cells, a resistant HCT8 colon carcinoma subline was developed by serial etoposide exposure. Endoretroviral
elements were detected by immunocytochemical staining, qPCR and ELISA. IC50-values of antiviral and cytostatic drugs in
HCT8 cells were determined by MTT proliferation assay. The antivirals-cytostatics interaction was evaluated by the
isobologram method.
Results: In this work, we show for the first time that HERV-WE1, HERV-FRD1, HERV-31, and HERV-V1 are a) simultaneously
expressed in treatment-naïve colon carcinoma cells and b) upregulated after cytostatic exposure, suggesting that these
retroviral elements are intimately related to chemotherapy resistance. We found a number of antiviral drugs to have
cytotoxic activity and the ability to force the downregulation of HERV proteins in vitro. We also demonstrate that the use
of different antiviral compounds alone or in combination with anticancer agents results in a synergistic antiproliferative
effect and downregulation of different endoretroviral elements in highly chemotherapy-resistant colorectal tumor cells.
Conclusions: Enhanced HERV-expression is associated with chemoresistance in colon carcinomas which can be
overcome by antiviral drugs alone or in combination with anticancer drugs. Therefore, the introduction of antiviral
compounds to the current chemotherapy regimens potentially improves patient outcomes.
Keywords: Human endogenous retroviruses, Chemotherapy resistance, Antiviral drugs
* Correspondence: david.diaz-carballo@marienhospital-herne.de
1Institute for Molecular Oncology and Experimental Therapeutics, Division of
Oncology and Hematology, Marienhospital Herne, Ruhr University of
Bochum, Medical School, Marienhospital Herne, Duengelstr. 33, 44623 Herne,
Germany
Full list of author information is available at the end of the article
© 2015 Díaz-Carballo et al. Open Access This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made
available in this article, unless otherwise stated.
Díaz-Carballo et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:81 
DOI 10.1186/s13046-015-0199-5
Background
Cancer chemotherapy is likely to be associated with the
development of cancer stem cell-like phenotypes. This
chemical stress can force the genesis of cell heterogen-
eity in the tumor that becomes manifest in its histology,
protein expression pattern, and genetic/epigenetic signa-
ture [1]. In addition, it is known that drug or ionizing
radiation exposure can induce the expression of viral
elements present in the cells [2, 3]. However, the rela-
tionship between the manifest endoretroviral spectrum
and the development of chemotherapy resistance has
not been concatenated until now.
Accounting for 8 % of the human genetic material, hu-
man endogenous retroviruses (HERVs) represent a foot-
print of ancestral germ-cell infections in which viruses
integrated into the host genome and were transmitted in
a Mendelian form to the progeny [4]. Structurally,
HERVs retain all retroviral hallmarks, including the gal,
pol & env genes flanked by non-coding long terminal
repeats (LTRs). Although most HERVs have lost the
capacity of horizontal transmission due to gene defects,
some have retained this ability despite their apparent
apathogenicity [5–7]. To ensure proliferation, they se-
questrate intact elements from co-expressed exoviruses
to form functional entities [8–10].
While organs like ovaries and testes as well as embry-
onic stem cells express HERV elements abundantly, ex-
pression is typically low or non-detectable in somatic
cells. Furthermore, it is known that HERV-W significantly
contributes to the differentiation of cytotrophoblasts into
syncytiotrophoblasts through the fusogenic properties of
the syncytins (HERV-WE1 & HERV-FRD), which are prod-
ucts of the viral envelope gene [11–18].
So far, the contribution of HERVs to normal cell physi-
ology remains largely unstudied. On the other hand, a
number of fossil HERVs have been linked to neoplastic
transformation that gives rise to breast and small-cell lung
carcinomas, renal carcinomas, leukemias, and other ma-
lignancies [5, 19–21]. For example, the overexpression of
HERV-H and HERV-V-3 was found to be correlated with
the development of colon carcinoma, although any rela-
tionship to chemotherapy resistance or tumor aggressive-
ness has not been reported so far [22, 23].
It was recently demonstrated that iRNA targeting
HERV-K can suppress tumor growth in melanoma
models, suggesting that the overexpression of particular
HERVs may play a crucial role in tumor physiology [24].
Consequently, interference with these viral elements via
antiviral agents could produce antitumoral effects. The
introduction of antiviral drugs such as ribavirin into the
therapy of tumors with high HERV expression (e.g. refrac-
tory AML) has shown complete and partial responses and
a reduction in overall levels of eIF4E [25–29]. Neverthe-
less, the influence of antiviral agents on the expression of
these viral elements and their potential anticancer activity
has not been reported yet.
Here, we show that cytostatic stress induces the
development of highly resistant, HERV-overexpressing
tumor cells. We determine the cytotoxic activity of
different antiviral agents and highlight their capacity to
shut down HERV expression. Finally, we demonstrate
that the combination of antiviral compounds and
antitumoral drugs reflects synergistic antiproliferative
effects in highly resistant, HERV-overexpressing colo-
rectal tumor cells.
Materials and methods
Cell cultures and patient samples
HCT8 colon carcinoma cells employed in this study
were obtained from the cell and tumor bank of the Uni-
versity of Duisburg-Essen, Medical School. Mononuclear
cells (MNC) were isolated from whole blood using Ficoll
(Sigma-Aldrich, Missouri, USA) gradient following the
manufacturer’s instructions. CD34+ cells were isolated
using magnetic bead kits (Milteny, Cologne, Germany)
following the kit instructions.
Patient samples
Ethical considerations This study was reviewed and ap-
proved by the Committee on Ethics of the Ruhr-University
of Bochum, Medical School (register numbers: 4042-11 and
5235-15). Written informed consent was obtained from
each participant. Informed written consent regarding eli-
gible subjects below 18 years was obtained from parents.
Samples were anonymised, coded and accessible only by re-
search staff. All patient samples were gathered by the div-
ision of visceral surgery, Marienhospital Herne, Germany.
The histopathological of samples were performed by the
institute of pathology of the Ruhr-University of Bochum,
Medical School.
IC50 values and induction of etoposide resistance
IC50 values were determined using the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
proliferation assay as described previously, and reported
as the mean of three independent experiments. Briefly,
cells in exponential growth phase were harvested,
washed with medium, and seeded in 96-well plates at
appropriate densities according to their growth kinetics.
After a conditioning period of 24 hours, cells were
exposed to increasing concentrations of cytostatics for
72 hours. The cultures were then incubated with MTT
(Sigma-Aldrich, Munich, Germany) dissolved in PBS at a
final concentration of 1 mg/ml for 4 hours. Supernatants
were aspirated and the purple formazan crystals dis-
solved in 100 μl of solubilization solution (10 % SDS in
DMSO, Sigma-Aldrich, Munich, Germany). The absorb-
ance was measured in a microtiter plate reader (Infinite
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F200 Tecan, Berlin, Germany) at 570 nm. Both methods
were formerly described [30, 31].
Resistance to etoposide in HCT8 cells was induced in the
same form previously described [1, 30, 32]. Briefly, IC50
values for cytostatics were determined by MTT assay. Ex-
ponentially growing cells were then exposed to 2× IC50 for
24 hours. For recovery, cells were washed and incubated
with drug-free culture medium until new colonies had
formed. This procedure was repeated several times, each
time doubling the original IC50 until 64× IC50 was reached.
The surviving cells were subjected to a resistance selection
by incubation with increasing concentrations of the re-
spective drugs (16× to 512× IC50) for 24 hours. Cells which
proliferated at higher drug concentrations (128×) within
one week were considered chemotherapy refractory. Resist-
ant colonies were then expanded in the continuous pres-
ence of cytostatics and used for molecular-biological
analysis, in particular for studying the expression of CSC
features. The resistance factor (RF) was determined by
MTT proliferation assay and reported as the IC50 iCSCs/
IC50 parental ratio. Using etoposide as chemoresistance-
inducer it is feasible to induce a wide HCT8 subpopulation
of cells (HCT8RETO) with cancer stem cell features (CSCs)
in a very short time. HCT8WT/RETO cells were cultured in
DMEM medium (Biochrom, Berlin, Germany) containing
10 % heat-inactivated fetal calf serum (FCS) and 15 μg/ml
Ciprobay (Bayer AG, Wuppertal, Germany).
Studies on the expression of human endogenous
retrovirus elements (HERVs) in colorectal carcinomas
(CRCs)
We analyzed the expression of HERV-WE1 and HERV-
FRD1 in patient samples as well in HCT8
WT/RETO colon
carcinoma cell line using both immunocytochemical
(ICC) and immunohistochemical (IHC) staining.
ICC and IHC staining was performed according to
standard protocols [1]. Briefly, ICC cells were grown in
chamber slides to appropriate densities, washed with
1× PBS, fixed with 4 % formaldehyde in PBS for 20 minutes,
rinsed twice with 1× PBS for 5 minutes, and blocked with
10 % normal goat serum (AbD Serotec, London, UK) at
room temperature for 60 minutes. For IHC, tissue samples
were fixed with 4 % formaldehyde in PBS and embedded in
paraffin. Paraffin tissue sections of 4 μm thickness were
baked overnight at 60 °C to firmly attach the sections to the
slides. After baking, the sections were deparaffinized in 2
changes of xylene-substitute (Thermo Scientific, London,
UK) solution for 10-15 min and rehydrated in a series of
graded ethanol solutions (100 %, 100 %, 95 %, 70 %, 50 %)
for 3 minutes each. HE staining was performed using con-
ventional techniques. For IHC, antigens were retrieved by
heating the sections for 30 minutes in 10 mM sodium cit-
rate buffer pH 9.0 at 95 °C in a domestic vegetable steamer.
The slides were washed twice in 1 × PBS for 5 minutes and
blocked for 60 minutes with 10 % normal goat serum at
room temperature. Primary antibodies (Bioss Antibodies,
Woburn, USA and Biorbyt, Cambridge, England) were ap-
plied overnight according to the manufacturers' recommen-
dations. On the next day, the slides were washed 3 times in
PBST (PBS/0.05 % Tween 20) for 5 minutes each and
rinsed in 1 × PBS for another 5 minutes. Conjugated sec-
ondary antibodies (Cell signaling, Cambridge, UK) diluted
in PBS/0.05 % Tween 20/2.5 % goat serum were incubated
for 120 minutes at room temperature according to the
manufacturers' recommendations. Next, the samples were
stained for 15 minutes with 1 μg/ml Hoechst 33258 diluted
in PBS in order to visualize the nuclei. The slides were then
washed 3 times in PBST (PBS/0.05 % Tween 20) for 5 mi-
nutes each and rinsed in 1 × PBS for another 5 minutes.
Tissue specimens were mounted in Faramound Mounting
medium (Dako) for visualization.
Differential expression of HERV transcripts in HCT8WT/RETO
colon carcinoma cells
RNA purification and cDNA synthesis
Total RNA was extracted with Trizol® (Life Technolo-
gies, California, USA). To eliminate genomic DNA con-
tamination, the eluted RNA containing 10 IU RNase
inhibitor was treated with 7 Kunitz units of RNase-free
DNase I (Qiagen, Hilden, Germany) in the appropriate
buffer and incubated at 25 °C for 20 minutes. The RNA
samples were then purified further on RNeasy mini col-
umns (Qiagen, Hilden, Germany) according to the man-
ufacturer’s instructions. RNA integrity was ascertained
by agarose gel electrophoresis and densitometric ana-
lysis. 1 μg of pure and intact RNA was used for first-
strand cDNA synthesis using the cDNA Reverse Tran-
scription Kit from Life Technologies, following the kit
instructions.
qPCR
HERV expression was monitored by qPCR with validated
primers and probes from Life Technologies (Cat. Nr.: 18S
Hs99999901_s1, HERV WE1 Hs01926764_u1, HERV-
FRD1 Hs01942443_s1, HERV3-1 Hs 04184598_s1 and
HERV-V1 Hs00708335_s1), using the Taqman PCR core
reagents according to the manufacturer’s recommenda-
tions. In addition, the expression of these HERV-elements
was confirmed using specific primers purchased from Bio-
mol (Hamburg, Germany). The primers details are
reflected in Table 1. The amplification of 25 ng of RNA
was performed in triplicate in a CFX96TM Real-Time Sys-
tem (Biorad Laboratories, California, USA). Results were
analyzed with CFX-ManagerTM Software Version 3.1
(Biorad Laboratories, California, USA). The evaluation of
HERV relative expression was determined using the Ct
comparative method.
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Analysis of the simultanean interaction of antiviral and
cytostatic drugs
Amantadine, ribavirin, pleconaril, lamivudine, and doxo-
rubicin were purchased from Sigma-Aldrich, acyclovir and
ganciclovir from HEXAL AG, Holzkirchen, Germany.
Retrovir was obtained from ViiV Healthcare, London, UK,
Foscavir from Clinigen Healthcare, Staffordshire, UK and
brivudine from Berlin Chemie, Germany. Etoposide and
cisplatin were purchased from TEVA GmbH and 5FU
from Medac, both Hamburg, Germany.
The simultaneous effect of antiviral drugs and cyto-
statics was analyzed by the isobologram method (50 %
isodose) as described previously [30]. Briefly, the IC50
for both substances were first determined using the
MTT proliferation assay. Applying fixed percentages of
the IC50 for the first drug (20, 40, 60, 80 and 100 %) and
varying the concentration of the second drug from 0.1
to 50 μM, the variation in the resulting IC50 was deter-
mined for every percentage. The same procedure was
carried out inversely for the second drug. Dose-response
curves were then plotted and evaluated.
Protein isolation and Western blot analysis
To evaluate the direct effect of antiviral drugs on the
expression of HERV proteins we exposure HCT8 cells to
amantadine, pleconaril and ribavirin alone or simultan-
eously at 1-fold their respective IC50-values for 24 hours.
3 × 106 HCT8WT/RETO cells growing exponentially in
75 cm2 TC flasks were incubated in medium containing
the respective IC50 of amantadine, pleconaril, and
Table 1 Real Time PCR primers used for the detection of HERVs. The accession, region, sequence, polarity and product size for the
primers used are reflected
Symbol Accession Region Forward Reverse Size (bp)
18S NR003286 1025-1513 tcaagaacgaaagtcggagg ggacatctaagggcatcaca 488
HERV-WE1 AF072506 290-463 gggttccatggttctcttct tggtgaaccacttccaagat 174
HERV-FRD1 NM207582 504-698 ctcattctcacgccttcact taattccgcctctatgcttg 195
HERV-V1 NM152473 1565-1757 gggcaaagattctgcaacta ttgtctggctacctgcctac 193
HERV-31 NM001007253 1377-1562 taaccagaaattgcctgagc gaagaggcggttagtgtgaa 186
Fig. 1 Overexpression of HERV-WE1 and HERV-FRD1 in colon adenocarcinoma patient sections analyzed by IHC. Both elements are principally
expressed in the villi, intervillar space and crypts of the large intestine especially in the tumor area, normal tissues are almost negative. Magnification
400x, n = 20 independent sections
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ribavirin alone or with all drugs simultaneously for
24 hours. Medium was then removed and the cells
washed twice with cold PBS. Protein extraction was
performed using RIPA buffer as previously described [1].
Briefly, pellets were lysed in RIPA buffer [150 mM NaCl,
1 mM EDTA, 1 % Triton X-100, 1 % sodium deoxycho-
late, 0.1 % SDS, 50 mM Tris-HCl pH 7.4] in the pres-
ence of a proteinase inhibitor cocktail according to the
manufacturer’s instructions (Roche Diagnostics GmbH,
Mannheim, Germany) for 30 minutes on ice and then
centrifuged for 20 minutes at 14 000 g, 4 °C. The ho-
mogenates were measured for protein content using
Bradford and normalized to the same protein concentra-
tion. Protein extracts (30 μg) were resolved by SDS-
PAGE in a 4–12 % gradient gel (Invitrogen, Karlsruhe,
Germany) using Tris-glycine (0.025 M Tris-HCl,
0.192 M glycine pH 8.5) buffer, and transferred over-
night to 0.2 μm nitrocellulose membrane (Pierce Protein,
Thermo Scientific Inc., MA, USA). Blots were blocked
with 5 % BSA or non-fat milk taking into consideration
the recommendations of the manufacturers of the pri-
mary and secondary antibodies. Primary antibodies were
purchased from Bioss Antibodies, Woburn, USA.
Conjugated secondary antibodies were obtained from
Cell Signaling and Jackson ImmunoResearch Europe
Ltd. (Suffolk, UK). Immunoblots were developed by
Western Lightning® Plus-ECL (Perkin Elmer, CA, USA)
using a ChemiDoc XRS+ system with Image Lab Version
2.0.1 software (Biorad, CA, USA).
Enzyme-linked immunosorbent assay (ELISA)
Differential HERV expression and its repression by anti-
viral drugs were monitored using an indirect ELISA
method. In brief, 96-well microtiter plates (Greiner
Bio-One GmbH, Frickenhausen, Germany) were coated
with protein homogenates (5 μg/100 μl) overnight at 4 °C.
Well contents were aspirated and the wells washed 3
times with washing buffer (PBS/0.05 % Tween 20). The
wells were then incubated with 300 μl blocking buffer
[PBS/0.05 % Tween 20/1 % bovine serum albumin (BSA)]
each at 37 °C for 1 h and then washed 3 times. Primary
antibodies diluted 100 μl in blocking buffer 1:500 were
added, followed by incubation at 37 °C for 1 h. The wells
were aspirated and washed three times followed by
Fig. 2 Differential expression of HERV-WE1 and HERV-FRD1 in HCT8
WT/RETO colon carcinoma cells analyzed by ICC. Cells growing on chamber slides
were labeled with anti-HERV-WE1 and anti-HERV-FRD antibodies. Wildtype cells express basal levels of both HERV elements while the HCT8
RETO
cells express high levels and develop hypertrophy. Magnification 400x, n = 3 independent experiments
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incubation with an HRP-conjugated secondary antibody
(Sigma-Aldrich) in 100 μl at 37 °C for 1 h, dilution
1:2000. The wells were washed 3 times and incubated
at 37 °C for 30 min with 100 μl of fresh 0.4 mg/ml o-
phenylenediamine and 0.4 mg/ml urea/H2O2 dissolved
in 0.05 M Na2HPO4/0.05 M citric acid adjusted to
pH 5. The color reaction was stopped with 50 μl of
1 M HCl per well, and the optical density measured
after 1 h at 492 nm (OD492) on an Infinite M200 mi-
crotiter plate reader (Tecan, Maennedorf, Switzerland).
Results were normalized using beta-actin as control
and presented as percent of expression.
Statistical analysis
Experiments were performed at least in triplicate and the
data given as means ± standard error of means (SEM), un-
less stated otherwise. Student’s t-test with four degrees of
freedom was used to compare independent groups. The
statistical analyses were performed with Sigma Plot 12




Fig. 3 Differential expression of HERVs in HCT8WT/RETO, analyzed by real-time PCR. a: Amplification pattern of different HERVs in CD34+ mononuclear cells
(MNC) from umbilical blood. The cells express all analyzed HERV variants. b: 18S endogenous control. c: Differential expression of HERV-WE1
(2−ΔΔCt 1.06). d: Degree of difference of HERV-FRD1 (2
−ΔΔCt 1.72). Degree of difference of HERV-V1 (e, 2
−ΔΔCt 3.87) and HERV 31
(f, 2−ΔΔCt 1.80) transcripts in HCT8 WT/RETO. In HCT8RETO, all HERV are overexpressed compared to HCT8WT. Red, WT; green, RETO,
n = 3 independent experiments
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value was considered *: significant (p < 0.05); **: very
significant (p < 0.01); ***: highly significant (p < 0.001).
ICC and IHC microscopy studies were descriptive and
therefore not analyzed statistically; the results shown
are representative of at least n = 3 independent
experiments.
Results
HERV expression in colorectal carcinoma patient material
The expression of the HERV elements WE1 and FRD was
monitored by IHC in human colorectal adenocarcinoma
paraffin sections. Both elements were found to be overex-
pressed in tumors as compared to the normal colon tis-
sues. Fig. 1 shows that the expression of both viral traces
was localized to the villi, intervillar regions and the crypts
of the large intestine, but confined to the tumor areas.
Overexpression of HERV-WE1 and HERV-FRD1 in HCT8
RETO
colorectal carcinoma cells
The anticancer drug etoposide is commonly not
employed in the treatment of colorectal carcinomas
(CRC). Nevertheless, this drug is associated with the
induction of cancer stem cell characteristics in several
tumors as previously described. In HCT8 colorectal
carcinoma cells, etoposide induces characteristics for
stemness, as judged by their self renewal capacity, colo-
nosphere formation, radioresistance and markedly re-
duced chemotherapy sensitivity as well as a defined set
of CSC-markers like EpCAM, Mucins 1 & 4, c-Myc,
Stat3, stem cell factor (SCF), Musashi, β-catenin, among
others (see Additional file 1). These cells showing CSC-
features were designated as HCT8RETO cells.
We investigated the differential expression of HERV-
WE1 and HERV-FRD1 in colon adenocarcinoma based
Fig. 4 In vitro cytotoxicity of amantadine, ribavirin and pleconaril in HCT8WT/RETO cells. Cytotoxicity was measured over 24 hours by MTT assay.
Amantadine and pleconaril show a specific activity in the highly chemotherapy-resistant subline. Values represent the means ± standard deviation
of at least n = 3 independent experiments




Fig. 5 (See legend on next page.)
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on the cell line HCT8WT/RETO. During development of
resistance against etoposide, the first observable change
was the emergence of a transitory cell hypertrophy as
depicted in Fig. 2, together with the overexpression of
several endoretroviral elements as observed by ICC.
Various HERVs transcripts are simultaneously expressed
in HCT8WT and overexpressed in HCT8RETO cells
Human stem cells have been described to express a
range of different HERVs. It is also known that these ele-
ments, especially HERV-H, are expressed in colon car-
cinomas, probably due to the presence of cancer stem
cells. The expression of different HERVs and a possible
relationship to chemosensitivity has not been reported
yet. For this purpose, we analyzed HCT8WT/RETO cells
for HERV mRNAs. Mononuclear CD34+ cells from um-
bilical cord blood served as positive control since these
cells were found to co-express a battery of HERV ele-
ments. It was striking, that expression of HERV mRNA
transcripts WE1 (Fig. 3c), FRD1 (Fig. 3d) 31 (Fig. 3e) and
V1 (Fig. 3f ) was significantly enhanced in HCT8
RETO
cells, compared to parental HCT8WT cells (range from
1.06 to 3.87-fold).
We next asked whether incubation with antiviral com-
pounds might have an impact on tumor biology and/or
proliferation of chemorefractory cancer cells in vitro.
Enhanced cytotoxic effect of antiviral compounds on
chemoresistant tumor cells in vitro
To get a first hint on the antiproliferative activity of anti-
viral compounds in colon carcinoma cells, we analyzed
antiviral drugs like amantadine, ribavirin, pleconaril,
lamivudine, acyclovir, ganciclovir, AZT, foscavir and bri-
vudine in HCT8WT/RETO cells. Of these, only three com-
pounds showed some degree of antiproliferative effect,
as defined by their IC50 values: amantadine, ribavirin
and pleconaril (Fig. 4). All other drugs did not show de-
tectable activity at concentrations up to 200 μg/ml (data
not shown) and therefore were excluded from further
analysis. In general, amantadine and pleconaril were the
most active compounds in the HCT8RETO cells (Fig. 4).
Synergistic cytotoxic effects between amantadine and
anticancer drugs in HCT8WT/RETO cells
We next questioned the potential interaction between
antiviral compounds and classical, clinically used anti-
cancer drugs in vitro. In this work results were only
shown for amantadine, but similar data were also
achieved for pleconaril and ribavirin, respectively.
In general, using the chemo-sensitive HCT8WT cell line
(Fig. 5, panels a, c and e), interaction between amantadine
and doxorubicin was slightly synergistic (panel a), between
amantadine and cisplatin (CP) additive (panel c), and re-
markable antagonistic activity was observed between
amantadine and 5FU (panel e), respectively. In contrast, in
the chemoresistant HCT8RETO cell line (Fig. 5, panels b, d
and f), synergistic interaction between amantadine and all
three anticancer drugs was shown, although synergism
was less pronounced using 5-fluorouracil (5FU) (panel f).
These results indicate that antiviral compounds like
amantadine do not only exhibited substantial cytotoxic ac-
tivity in chemoresistant tumor cells by itself, but also en-
hance the cytotoxic efficacy of anticancer drugs in vitro.
We also explored the potential synergistic antiprolifer-
ative effects by combining different antiviral compounds
by using their specific IC50. As expected, amantadine,
pleconaril and ribavirin as single drugs reduced cell sur-
vival by about 50 %. Enhanced cytotoxicity in HCT8RETO
cells was only detectable for amantadine and pleconaril.
In general, combination of antiviral compounds (Fig. 6,
panel b) resulted in enhanced cytotoxicity, especially for
amantadine-containing doublets or even triplets. How-
ever, all antiviral combinations did not show enhanced
activity in chemo-resistant HCT8RETO cells, compared
to chemo-sensitive HCT8WT cells, indicating unspecific
cytotoxic effects of antiviral compounds rather than add-
itional suppression of HERV-protein expression.
In addition we analyzed if the antiviral compounds alone
or applied as polychemotherapy exerts effects on the regu-
lation of HERVs proteins in HCT8RETO cells, which abun-
dantly expressed different HERVs entities. We found that
amantadine, pleconaril and ribavirin alone or in combin-
ation applied simultaneously, significantly downregulated
the protein expression of HERVs as reflected in Fig. 6, panel
b. This effect was drastically observed for the simultanean
incubation of all antivirals studied (Fig. 6, panels b & c).
These results certainly demonstrated that cytotoxicity of
antiviral compounds in chemoresistant HCT8RETO cells is
also associated with downregulation of HERV-proteins.
Downregulation of HERV-proteins upon exposure of
chemo-resistant HCT8RETO cells to the antiviral compound
amantadine
We have already shown enhanced cytotoxicity of anti-
viral compounds in chemoresistant HCT8RETO cells
(See figure on previous page.)
Fig. 5 Isobologram showing the in vitro interaction between amantadine and doxorubicin, cisplatin or 5FU in HCT8WT and HCT8RETO cells.
Dose-response curves are based on the respective IC50 values calculated after 24 hours of incubation. Amantadine-doxorubicin are synergistic in
HCT8 WT/RETO (a & b). Amantadine-cisplatin are additive in HCT8 wildtype (c) and synergistic in HCT8RETO (d). Amantadine-5FU are synergistic in
RETO (f) but antagonistic in HCT8WT (e). n = 3 independent experiments
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in vitro (Fig. 4). Furthermore, we shown that amantadine
is able to reduce significantly the HERV protein expres-
sion at 1-fold its IC50 as observed by Western blotting
(Fig. 6, panel b & c). Fig. 7 depicts the semi-quantification
of the effect of amantadine in HCT8WT/RETO cells as
assayed by ELISA. As expected, the protein expression
of HERV-WE1 and FRD1 is markedly enhanced in
HCT8RETO cells (panel 3) compared to HCT8WT cells
(panel 1). Upon incubation with amantadine, pronounced
reduction of HERV-WE1 and -FRD1 protein expression
was only detectable in HCT8RETO cells. Comparable data
were achieved for HERV-WE1 and FRD1 at the RNA
levels (data not shown).
Discussion
In this study, we have demonstrated that enhanced ex-
pression of various HERV proteins is not only detectable
in colon cancer cells, but might also have therapeutic
implications for CRC patients especially in chemorefrac-
tory tumors.
A number of HERVs have been found to be upregu-
lated during carcinogenesis in tumors derived from
tissues that normally show no or only basal expres-
sion of these elements. For example, HERV-K tran-
scripts of the Env protein, while entirely absent in
normal breast tissue, were demonstrated to be overex-
pressed in almost all breast carcinomas [33–35]. In
addition, the expression of HERV-H and HERV-3-1 in
colon carcinomas has been reported [22, 23].
Recently, we described a method to induce multi-
resistant cancer cells that express several CSC tissue-
related markers as well as stemness features like sphere
formation, radio- and chemoresistance [1, 32]. These
cells also showed an up-regulation of a set of HERVs.
Moreover, HERVs expression has been also linked to
stemness in both normal and cancer cells [36].
Colon adenocarcinoma paraffin sections showed
significant expression of HERV-WE1 and HERV-FRD1.
These viral transcripts, as well as HERV 31 and
HERV V1, were also expressed in HCT8
WT and over-
expressed up to three times in chemotherapy refrac-
tory HCT8RETO cells, suggesting a relationship to
chemoresistance. Consequently, additional HERV ele-
ments might contribute to carcinogenesis and chemo-
therapy resistance [4, 5, 10, 11, 21].
So far, a possible relationship of HERVs with
chemotherapy resistance might be a result of the
interaction of these proteins with cell membrane
structure. Hypothetically, the ability of HERV-WE1
and HERV-FRD proteins to promote cell-cell fusion
(See figure on previous page.)
Fig. 6 Cytotoxic effect of antiviral drugs and their influence in the expression of HERV proteins in HCT8 colon carcinoma cells. Simultaneous
incubation of HCT8WT/RETO with amantadine, ribavirin and pleconaril based on the IC50 values calculated for the drugs applied alone or in combination
for 24 hours. a: Influence of Amantadine, Pleconaril and Ribavirin in the expression of HERVs analyzed by ELISA in HCT8WT/RETO cells. b: Down
regulation of HERVs proteins after antiviral exposure analyzed by Western blot. c: relative expression of HERVs under the influence of antiviral drugs.
Amantadine-pleconaril show a potentiation of circa 35 % in HCT8WT and 20 % in HCT8RETO. Amantadine-ribavirin have a potentiation of circa 25 % in
HCT8WT and 10 % in HCT8RETO. The three-way combination ARP was the most effective. Results are representative of n = 3 independent experiments
Fig. 7 Effect of amantadine on HERV protein expression in HCT8WT/RETO analyzed by ELISA. The expression of both HERV-WE1 and HERV-FRD1 is
downregulated after incubation with amantadine at 2 x IC50 for 24 hours. Expression is reduced to basal levels in HCT8
RETO. The results are given
in percent in relation to the expression of beta-actin as endogenous control
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and generation of multinucleated giant cancer cells
could represent an alternative membrane-mediated
defense mechanism [12, 14, 15, 37, 38]. Moreover,
HERV overexpression could serve as a benchmark to
monitor therapy resistance.
The first evidence for the impact of HERV gene repres-
sion on the inhibition of tumor cell growth came from the
group of Thierry Heidmann [24], who used iRNA directed
against HERV-K in a melanoma model. Wang-Johanning
and coworker reported on the immunotherapeutic poten-
tial of anti-human endogenous retrovirus-K envelope
protein antibodies in targeting breast tumors in vitro and
in vivo. These anti-HERV-K-specific monoclonal anti-
bodies inhibited tumor growth and induced apoptosis of
breast cancer cells [39].
These data served as a rationale to examine antiviral
drugs for antiproliferative activity and downregulation of
HERV proteins in a panel of HERV-expressing chemore-
sistant cancer cell lines. Among these compounds, the
structurally unrelated amantadine, ribavirin and pleco-
naril were found to be the most active, with IC50 values
below 20 μg/ml, that might be clinically relevant.
Amantadine is approved for use as antiviral and antipar-
kinsonian drug. No primary mechanism of action has
been described so far, but it its known that its interference
with Influenza virus protein M2 plays an important role in
repressing both the early and late phase of viral replication
cycle. We focused our studies on amantadine because we
previously have been investigating several PPAP com-
pounds (polycyclic polyprenylated acylphloroglucinols)
such as nemorosone and plukenetione A, which structur-
ally share the adamantane backbone. We already reported
on the antitumoral and antiretroviral activity of these
drugs, which we found to inhibit HIV. Moreover, PPAPs
were recently described as selective agents in highly resist-
ant neuroblastoma entities [40–43], exerting a pleiotropic
effect that involves the downregulation of transcription
factors which may interact with viral promoters like Myc,
Myb and Stat1/3 [44].
The combination of amantadine with doxorubicin,
cisplatin and 5FU acted synergistically in etoposide-
refractory HCT8RETO, i.e. amantadine boosts the cyto-
toxicity of these cytostatics in resistant cells.
We also addressed the combination of amantadine,
ribavirin and pleconaril on overall cytotoxicity in
HCT8WT/RETO cells. Enhanced efficacy was observed for
the combinations AP (amantadine-pleconaril), AR
(amantadine-ribavirin) and ARP (amantadine-ribavirin-
pleconaril), the latter being the most cytotoxic.
In conclusion, our data suggest that enhanced expres-
sion of various HERV proteins might have therapeutic
implications in colorectal cancer. Therefore, the intro-
duction of antiviral compounds to the current chemo-
therapy regimens potentially improves patient outcomes.
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